Researchers have rallied round a promising molecule for rescuing dying nerves. But getting it into the brain remains a daunting challenge, finds Brian Vastag.
This is a preview of subscription content, log in via an institution to check access.
References
Airaksinen, M. S. & Saarma, M. Nature Rev. Neurosci. 3, 383-394 (2002).
Gill, S. S. et al. Nature Med. 9, 589-595 (2003).
Love, S. et al. Nature Med. 11, 703-704 (2005).
Pardridge, W. M., Kang, Y. S., Buciak, J. L. & Yang, J. Pharm. Res. 12, 807-816 (1995).
Pardridge, W. M. & Boado, R. J. Pharm. Res. 26, 2227-2236 (2009).
Additional information
Brian Vastag is a freelance reporter in Washington DC.
Related links
Related links
Related links in Nature Research
Related external links
Rights and permissions
About this article
Cite this article
Vastag, B. Biotechnology: Crossing the barrier. Nature 466, 916–918 (2010). https://doi.org/10.1038/466916a
Published:
Issue Date:
DOI: https://doi.org/10.1038/466916a
- Springer Nature Limited
This article is cited by
-
A network map of GDNF/RET signaling pathway in physiological and pathological conditions
Journal of Cell Communication and Signaling (2023)
-
Incomplete copolymer degradation of in situ chemotherapy
Journal of Materials Science: Materials in Medicine (2018)
-
Challenges and Promises in the Development of Neurotrophic Factor-Based Therapies for Parkinson’s Disease
Drugs & Aging (2014)
-
Engaging neuroscience to advance translational research in brain barrier biology
Nature Reviews Neuroscience (2011)